Ambeed.cn

首页 / / / / LY2109761

LY2109761 {[allProObj[0].p_purity_real_show]}

货号:A225920

LY2109761是一种口服活性和选择性的TGF-β I/II型受体抑制剂,其Ki值分别为38 nM和300 nM。

LY2109761 化学结构 CAS号:700874-71-1
LY2109761 化学结构
CAS号:700874-71-1
LY2109761 3D分子结构
CAS号:700874-71-1
LY2109761 化学结构 CAS号:700874-71-1
LY2109761 3D分子结构 CAS号:700874-71-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

LY2109761 纯度/质量文件 产品仅供科研

货号:A225920 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 ALK1 ALK2 ALK3 ALK4 ALK6 Smad3 TGF-β TGFβRI/ALK5 TGFβRII 其他靶点 纯度
LDN193189 ++++

ALK1, IC50: 0.8 nM

++++

ALK2, IC50: 0.8 nM

+++

ALK3, IC50: 5.3 nM

+++

ALK6, IC50: 16.7 nM

99%+
LDN-212854 ++++

ALK1, IC50: 2.4 nM

++++

ALK2, IC50: 1.3 nM

+

ALK3, IC50: 85.8 nM

+

ALK4, IC50: 2133 nM

+

ALK5, IC50: 9276 nM

99%+
ML347 ++

ALK1, IC50: 46 nM

++

ALK2, IC50: 32 nM

98%
K02288 ++++

ALK1, IC50: 1.8 nM

++++

ALK2, IC50: 1.1 nM

++

ALK3, IC50: 34.4 nM

+++

ALK6, IC50: 6.4 nM

99%+
LDN-193189 dihydrochloride ++++

ALK1, IC50: 0.8 nM

++++

ALK2, IC50: 0.8 nM

+++

ALK3, IC50: 5.3 nM

+++

ALK6, IC50: 16.7 nM

99%
LDN-214117 ++

ALK2, IC50: 24 nM

98%
DMH-1 +

ALK2, IC50: 107.9 nM

99%+
SB-505124 +

ALK4, IC50: 129 nM

++

ALK5, IC50: 47 nM

99%+
Vactosertib +++

ALK4, IC50: 13 nM

+++

ALK5, IC50: 11 nM

99%+
Alantolactone 98%
SIS3 97%
Pirfenidone 98%
Hesperetin 97%
RepSox ++++

TGFβR1(ALK5), IC50: 4 nM

98%
GW788388 +++

ALK5, IC50: 18 nM

98%
LY364947 ++

TGFβRI, IC50: 59 nM

+

TGFβRII, IC50: 0.4 μM

98%
SD-208 ++

TGF-βRI (ALK5), IC50: 48 nM

98%
SB-525334 +++

TGFβR1(ALK5), IC50: 14.3 nM

99%+
LY2109761 ++

TβRI, Ki: 38 nM

+

TβRII, Ki: 300 nM

99%+
Galunisertib ++

TβRI, IC50: 56 nM

98%
SB 431542 +

ALK5, IC50: 94 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

LY2109761 生物活性

靶点
  • TGFβRII

    TβRII, Ki:300 nM

  • TGFβRI/ALK5

    TβRI, Ki:38 nM

描述 The TGF-β pathway regulates a wide variety of cellular processes in many different cell types and biological contexts. There are three identified TGF receptor ligands, TGF-β1, 2, and 3. Activated TGF-β ligands can interact with TGF-β type II receptors (TβRII), then recruit and phosphorylate the TGF-β type I receptors (also called as TβRI or ALK5). In turn, activated TβRI phosphorylates SMAD2 and SMAD3 at C-terminal serine residues. Following that, phosphorylated SMAD and SMAD3 assemble into heterodimeric and trimeric complexes with SMAD4. Then the trimeric complex translocates into the nucleus and regulates the expression of TGF-β target genes[2]. LY2109761 is a dual inhibitor of TGF-βRI and TGF-βRII with Ki values of 38 and 300nM (measured by in vitro kinase assay). Pre-treatment with LY2109761 of 5uM concentration for 24h (serum free) can abolish the p-smad2 induced by TGF-β receptor which activated by TGF-β/serum in the following 30min in L3.6pl/GLT cells. Inhibition of TGF-βRI/II pathway with LY2109761 (5uM) significantly enhanced the anoikis in L3.6pl/GLT cells for 8h. LY2109761 of 5uM for 48-hour treatment can abolish the TGF-β1–stimulated migration and invasiveness of L3.6pl/GLT cells, the metastatic variant of pancreatic cancer cells. 50mg/kg of LY2109761 orally given to mice twice a day, 5 days per week for 4 weeks, shows antimetastatic effect in pancreatic cancer cell spontaneous metastasis models[1]. The invasiveness of the embryonic chicken vasculature by HLE tumors were decreased with treatment of 0.1uM LY2109761 for 48h, showing that LY2109761 can inhibit HLE tumors invading stroma and blood vessels[3].
作用机制 LY2109761 binds to the ATP binding site of the TGF-β R1 kinase domain. [4]

LY2109761 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
10A/HER2YVMA 0.1-0.5 μM Growth Inhibition Assay 9 d reduces the size, invasiveness and cell number of colonies 20383197
HepG2 10 μM  Function Assay 2 h inhibits autophagy induction by galangin 25268046
HLE 0.01-100 nM Function Assay 48 h inhibits the migration in a dose-dependent manner 20844878
HLE 0.001-20 μM Cytotoxity Assay 48 h induces cell cytotoxity in a dose-dependent manner 18318443

LY2109761 动物研究

Dose Mice: 50 mg/kg - 100 mg/kg[5] (p.o.)
Administration p.o.

LY2109761 参考文献

[1]Melisi D, Ishiyama S, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008 Apr;7(4):829-40.

[2]Colak S, Ten Dijke P, et al. Targeting TGF-β Signaling in Cancer. Trends Cancer. 2017 Jan;3(1):56-71.

[3]Fransvea E, Mazzocca A, et al. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology. 2009 Mar;49(3):839-50.

[4]Li HY, McMillen WT, et al. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. J Med Chem. 2008 Apr 10;51(7):2302-6.

LY2109761 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.26mL

0.45mL

0.23mL

11.32mL

2.26mL

1.13mL

22.65mL

4.53mL

2.26mL

LY2109761 技术信息

CAS号700874-71-1
分子式C26H27N5O2
分子量 441.525
别名
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Store in freezer, under -20°C

溶解度

DMSO: 5 mg/mL(11.32 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+water 0.5 mg/mL clear

PO 0.5% CMC-Na 41 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。